Role of phototherapy in the era of biologics - 19/07/20
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
Phototherapy is a safe and effective treatment for many dermatologic conditions. With the advent of novel biologics and small molecule inhibitors, it is important to critically evaluate the role of phototherapy in dermatology. Surveys have shown that many dermatology residency programs do not dedicate time to teaching residents how to prescribe or administer phototherapy. Limitations of phototherapy include access to a center, time required for treatments, and insurance approval. Home phototherapy, a viable option, is also underused. However, it should be emphasized that modern phototherapy has been in use for over 40 years, has an excellent safety profile, and does not require laboratory monitoring. It can be safely combined with many other treatment modalities, including biologics and small molecule inhibitors. In addition, phototherapy costs significantly less than these novel agents. Dermatologists are the only group of physicians who have the expertise and proper training to deliver this treatment modality to our patients. Therefore, to continue to deliver high-quality, cost-effective care, it is imperative that phototherapy be maintained as an integral part of the dermatology treatment armamentarium.
Le texte complet de cet article est disponible en PDF.Key words : biologics, broadband ultraviolet B, excimer, narrowband ultraviolet B, phototherapy, psoralen plus UVA, psoriasis, ultraviolet A1
Abbreviations used : BB-UVB, CR, IL, NB-UVB, PASI, PUVA, UV, UVB
Plan
Funding sources: None. |
|
Disclosure: Dr Lyons is a subinvestigator for Incyte, Beiersdorf, Unigen Inc, General Electric, Lenicura, Estée Lauder, miRagen, Biofrontera, Pfizer, and L'Oréal. Dr Hamzavi is an investigator for Patient-Centered Outcomes Research Institute, Incyte Corporation, Beiersdorf, Estée Lauder, Unigen Inc, Ferndale Healthcare Inc, Pfizer, Allergan, and Johnson & Johnson. Dr Lim is an investigator for Incyte, Beiersdorf, L'Oréal, Pfizer, and PCORI; has served as consultant for Pierre Fabre, ISDIN, Ferndale, and Galderma; and has participated as a speaker in general educational session for Pierre Fabre, Eli Lilly, Johnson & Johnson, and Ra Medical System. Dr Torres has no conflicts of interest to declare. |
|
IRB approval status: Not applicable. |
|
Reprints not available from the authors. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?